Capecitabine (X) is resource saving compared with iv bolus 5-FU/LV in adjuvant chemotherapy for Dukes' C colon cancer patients: Medical resource utilization (MRU) …
JJ McKendrick, J Cassidy… - Journal of Clinical …, 2004 - ascopubs.org
3578 Background: Treatment resource use has important implications for the total costs of
therapy and quality of life/clinical outcomes. Treatment convenience impacts patient
satisfaction and compliance. The X-ACT trial aimed to replace intravenous (iv) 5-FU/LV with
oral X, an effective 1st line treatment in metastatic colorectal cancer. Methods: MRU was
measured in the trial, which compared 6 months of twice-daily oral X 1,250 mg/m2 d1–14
every 3 weeks (n= 993) with iv 5-FU/LV (n= 974; Mayo Clinic regimen). Information was …
therapy and quality of life/clinical outcomes. Treatment convenience impacts patient
satisfaction and compliance. The X-ACT trial aimed to replace intravenous (iv) 5-FU/LV with
oral X, an effective 1st line treatment in metastatic colorectal cancer. Methods: MRU was
measured in the trial, which compared 6 months of twice-daily oral X 1,250 mg/m2 d1–14
every 3 weeks (n= 993) with iv 5-FU/LV (n= 974; Mayo Clinic regimen). Information was …
以上显示的是最相近的搜索结果。 查看全部搜索结果